<DOC>
	<DOC>NCT00560781</DOC>
	<brief_summary>This study will test the therapeutic potential of augmenting a stable SSRI regimen with the neurosteroid pregnenolone to reduce cognitive symptoms and PTSD symptoms in patients diagnosed with PTSD.</brief_summary>
	<brief_title>Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs</brief_title>
	<detailed_description>See brief summary</detailed_description>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<criteria>1. 1865 years of age, any ethnic group, either sex 2. DSMIV diagnosis of PTSD by MINI (see schedule of events) 3. No change in SSRI medications for &gt; 4 weeks. 4. No anticipated need to alter any psychotropic medications for the 10week duration of the study. 5. Ability to fully participate in the informed consent process, or have a legal guardian able to participate in the informed consent process. 1. Unstable medical or neurological illness, including seizures, CVA, prostate or breast cancer 2. Use of oral contraceptives or other hormonal supplementation such as estrogen. 3. Significant suicidal or homicidal ideation. 4. Concomitant medications for medical conditions will be addressed on a casebycase base to determine if exclusionary. 5. Current DSMIV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition; history of substance dependence within the last 3 months 6. Female patients who are pregnant or breastfeeding. 7. Known allergy to study medication. 8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone, clozapine, etc.) will be excluded, as suggested by the FDA; patients taking these agents will not be eligible for this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Pregnenolone</keyword>
	<keyword>Cognition</keyword>
</DOC>